Intermittent Intraputamenal Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease: Seeking the Path to Neurorestoration

Affiliations

Nicholas Cothros et al. Mov Disord Clin Pract. 2019.

. 2019 Apr 1;6(4):280-281.

doi: 10.1002/mdc3.12757. eCollection 2019 Apr.

¹ Movement Disorders Program, Department of Clinical Neurosciences University of Calgary Calgary Alberta Canada.

No abstract available

Keywords: Parkinson's disease; clinical trial; glial cell line–derived neurotrophic factor (GDNF); intraputamenal infusion.

Conflict of interest statement

The authors report no sources of funding and no conflicts of interest.

1. Penttinen AM, Parkkinen I, Voutilainen MH, et al. Pre‐α‐pro‐GDNF and Pre‐β‐pro‐GDNF isoforms are neuroprotective in the 6‐hydroxydopamine rat model of Parkinson's disease. Front Neurol 2018;9:457. - PMC - PubMed
1. Bourque MJ, Trudeau LE. GDNF enhances the synaptic efficacy of dopaminergic neurons in culture. Eur J Neurosci 2000;12:3172–3180. - PubMed
1. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line‐derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130–1132. - PubMed
1. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line‐derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59:459–466. - PubMed
1. Whone A, Luz M, Boca M, et al. Randomized trial of intermittent intraputamenal glial cell line‐derived neurotrophic factor in Parkinson's disease. Brain 2019;142:512–525. - PMC - PubMed